Critical Review: Mind Medicine (MindMed) (MNMD) & Its Competitors

Mind Medicine (MindMed) (NASDAQ:MNMD – Get Rating) is one of 49 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its rivals? We will compare Mind Medicine (MindMed) to related businesses based on the strength of its dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Institutional and Insider Ownership

10.8% of Mind Medicine (MindMed) shares are owned by institutional investors. Comparatively, 19.0% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 26.5% of shares of all “Medicinals & botanicals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Mind Medicine (MindMed) and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mind Medicine (MindMed)	0	0	2	0	3.00
Mind Medicine (MindMed) Competitors	265	672	671	26	2.28

Mind Medicine (MindMed) presently has a consensus price target of 8.00, indicating a potential upside of 834.47%. As a group, “Medicinals & botanicals” companies have a potential upside of 104.49%. Given Mind Medicine (MindMed)’s stronger consensus rating and higher possible upside, research analysts clearly believe Mind Medicine (MindMed) is more favorable than its rivals.

Earnings and Valuation

This table compares Mind Medicine (MindMed) and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mind Medicine (MindMed)	N/A	-$93.04 million	-3.72
Mind Medicine (MindMed) Competitors	$238.90 million	-$88.34 million	-7.83

Mind Medicine (MindMed)’s rivals have higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Mind Medicine (MindMed) and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mind Medicine (MindMed)	N/A	-55.27%	-51.10%
Mind Medicine (MindMed) Competitors	-179.06%	-256.89%	-16.07%

About Mind Medicine (MindMed) (Get Rating)

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.